Conceptos Categóricos

ANALIZAN LAS CARACTERISTICAS DE LA VACUNA CUADRIVALENTE CONTRA EL HPV Y SU USO EN HOMBRES Y MUJERES

ANALIZAN LAS CARACTERISTICAS DE LA VACUNA CUADRIVALENTE CONTRA EL HPV Y SU USO EN HOMBRES Y MUJERES

(especial para SIIC © Derechos reservados)
En estos trabajos se presenta una revisión de la información disponible acerca de la eficacia, inmunogenicidad y reactogenicidad de las dos vacunas contra el HPV que han sido elaboradas para prevenir el cáncer de cuello uterino. Se discute el valor relativo de la vacunación contra el HPV en los lugares donde la detección sistemática por citología con Pap se lleva a cabo de rutina y en aquellos otros donde esta técnica está disponible de manera selectiva.
Autor:
Diane M Harper
Columnista Experta de SIIC

Institución:
University of Missouri-Kansas


Artículos publicados por Diane M Harper
Recepción del artículo
4 de Agosto, 2009
Aprobación
23 de Junio, 2011
Primera edición
14 de Marzo, 2012
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
Las enfermedades asociadas con los tipos 16 y 18 del HPV, que causan cáncer, y las asociadas con los tipos 6 y 11, que causan condiloma, se encuentran tanto en hombres como en mujeres. El cáncer de cuello uterino y sus precursores se atribuyen completamente a la infección oncogénica por HPV. El cáncer de cuello uterino contribuye con el 88% de la carga mundial de cánceres asociados con este virus. El cáncer de pene, vulva, vagina, ano y orofaringe se atribuyen en distinta medida al HPV oncogénico y, combinados, contribuyen con un 3% de la carga económica generada por las enfermedades asociadas con el virus. Las verrugas genitales y la papilomatosis respiratoria contribuyen con un 5% de dicha carga. Gardasil tendrá una mayor repercusión clínica en mujeres que no tienen acceso a la detección sistemática de rutina de la citología cervical y para el subgrupo de hombres que tienen sexo con otros hombres. La repercusión sobre las mujeres que ya están participando de programas de detección sistemática para el cáncer de cuello uterino será mucho menor. Esta revisión trata en detalle la información conocida hasta la fecha sobre la eficacia, inmunogenicidad y seguridad de Gardasil en las poblaciones estudiadas.

Palabras clave
varones, mujeres, condiloma, prevención del cáncer de cuello uterino, neoplasia intraepitelial cervical


Artículo completo

(castellano)
Extensión:  +/-22.64 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
HPV diseases associated with cancer-causing HPV types 16 and 18, or condyloma-causing HPV types 6 and 11 are found in males and females. Cervical cancer and its precursors are entirely attributed to oncogenic HPV infection. Cervical cancer contributes 88% of the worldwide burden of HPV associated cancers. Penile, vulvar, vaginal, anal, and oropharyngeal cancers are unequally attributed to oncogenic HPV and, all combined, contribute 3% of the economic burden of HPV associated diseases. Genital warts and respiratory papillomatosis contribute 5% of the economic burden of HPV associated diseases.
The vaccine will have the largest clinical impact on women who do not have access to routine cervical cytology screening and to the subset of men who have sex with men. The vaccine's impact on women already participating in cervical cancer screening programs will be much smaller. This review will detail the evidence known to date about the efficacy, immunogenicity and safety of the quadrivalent vaccine in the studied populations.

Key words
male, female, condyloma, cervical cancer prevention, cervical intraepithelial neoplasia


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Infectología, Obstetricia y Ginecología
Relacionadas: Atención Primaria, Inmunología, Medicina Familiar, Salud Pública, Urología



Comprar este artículo
Extensión: 22.64 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Diane M Harper, University of Missouri-Kansas School of Medicine
, MO 64139, 7900 Lee's Summit Road, Kansas, EE.UU.
Bibliografía del artículo
1. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV.. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244-65, 2002.

2. Castellsagué X, Díaz M, de Sanjosé S et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.
J Natl Cancer Inst 98(5):303-15, 2006.

3. Muñoz N, Castellsagué X, de González AB, Gissmann L Chapter 1: HPV in the etiology of human cancer. Vaccine 24 Suppl 3:S3/1-10, 2006.

4.* Myers ER. The economic impact of HPV vaccines: not just cervical cancer. Am J Obstet Gynecol 198(5):487-8, 2008.
* This editorial puts the costs of non-cervical cancer prevention into perspective with cervical cancer prevention.

5. Parkin DM, Bray F. Chapter 2. The burden of HPV-related cancers. Vaccine 24Suppl 3:S3/11-25, 2006.

6. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 191(1):105-113, 2004.

7. Eversole GM, Moriarty AT, Schwartz MR, et al. Practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch Pathol Lab Med 134:331-5, 2010.

8. Sawaya GF, Grimes DA. New technologies in cervical cytology screening: a word of caution. Obstet Gynecol 94(2):307-10, 1999.

9. **Berkhof J, Bogaards J, Coupé V, Meijer CJM. Modelling the influence of screening uptake on the future incidence of cervical cancer and the cost-effectiveness of HPV vaccination. 26th International Papillomavirus Conference, Montreal, Canada, (July 3-8, 2010).
** This work is critically important to understanding the limited usefulness of Gardasil in industrialized countries with cervical cancer screening programs.

10. *Harper DM, Nieminen P, Paavonen J, Lehtinen M. Cervical cancer incidence can increase despite HPV vaccination. Lancet Infect Dis 10(9):594-5, 2010.
*This work highlights that cervical cancer has increased in the past when women no longer participate in routine Pap screening.

11. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 198:500.e1-7; 2008.

12. Herrero R, Castellsagué X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95:1772-83, 2003.

13. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781-9, 2010.

14. Ramqvist T, Dalianis T. Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis (2010). [serial on the Internet]. http://www.cdc.gov/EID/content/16/11/1671.htm [accessed October 31, 2010].

15. Sturgis EM, Dahlstrom KR. Inaccurate assumptions about oropharyngeal cancer. BMJ 339:b4525, 2009.

16. Ho KS, Cranston RD. Anal cytology screening in HIV-positive men who have sex with men: what's new and what's now? Curr Opin Infect Dis 23(1):21-5, 2010.

17. *Piketty C, Selinger-Leneman H, Grabar S et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 22:1203-11, 2008.
*This work indicates that the incidence of anal cancer in this subpopulation is nearly as high as cervical cancer was prior to organized screening programs.

18. *Sutcliffe CG, Moss WJ. Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis 10(9):630-42, 2010.
*This work indicates the importance of boosters.

19. Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS 118:450-4, 2010.

20. Campisi P, Hawkes M, Simpson K. Canadian Juvenile Onset Recurrent Respiratory Papillomatosis Working Group. The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database. Laryngoscope 120:1233-45, 2010.

21. Verguts MM, Genbrugge E, de Jong FI. Treatment results in adult-onset recurrent respiratory papillomatosis. B-ENT 5:137-41, 2009.

22. Kashima HK, Shah F, Lyles A, et al. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 102:9-13, 1992.

23. Insinga RP, Dasbach EJ, and Myers ER. The Health and Economic Burden of Genital Warts in a Set of Private Health Plans in the United States. Clinical Infectious Diseases 36:1397-1403, 2003.

24. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 200(7):1059-67, 2009.

25. Monteiro EF, Lacey CJ, Merrick D. The interrelation of demographic and geospatial risk factors between four common sexually transmitted diseases. Sex Transm Infect 81:41-6, 2005.

26. Harper DM and Vierthaler SL. Cervarix. Expert Reviews, 2010.

27. *Harper DM, Williams KB. Prophylactic HPV Vaccines: Current Knowledge of Impact on Gynecologic Premalignancies. Discovery Medicine 10:7-17, 2010.
*This review highlights the importance of disclosing all benefits and risks of HPV vaccination.

28. **Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modeling analyses. PLoS Med 3:e138, 2006.
**This work is one of many that highlights the loss of cost effectiveness if Gardasil duration of efficacy is less than 15 years.

29. Gardasil [Package Insert]. Whitehouse Station, NJ: Merck & Co., Inc. 2009.

30. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 198:827-35, 2008.

31. Trottier H, Mahmud S, Prado JC, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 197:1436-47, 2008.

32. **Palefsky J. Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men. 26th International Papillomavirus Conference, Montreal, Canada, (July 3-8, 2010).
**This work presented the important efficacy against anal precancers in the MSM population.

33. **Palefsky, J. Quadrivalent HPV vaccine efficacy against anal intraepithelial neoplasia in men having sex with men. Presentation SS19-2. EuroGin, Monte Carlo, Monaco, (Feb 17-20, 2010).
**This work presents different information about the efficacy of Gardasil for preventing anal precancers in MSM than ref 32.

34. **Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines 5(10):696-704, 2009.
** This work shows that women are infected with the same type of HPV as they have been previously, and that Gardasil offers protection for this new exposure despite prior exposure.

35. **Koutsky LA for the FUTURE II Study Group: Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. N Engl J Medicine 356:1915-1927, 2007.
**Key paper of evidence for Gardasil use.

36. Garland SM, Hernandez-Avila M, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928-43, 2007.

37. Wilkin T, Lee JY, Lensing SY et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 202(8):1246-53, 2010.

38. *Calugar A. Vaccine Safety Update: VAERS. DHHS/CDC ACIP Meeting Minutes. October 2008; pp 49-51.
*Male side effect of GBS.

39. Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 12(5-6):343-51, 2009.

40. Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 27(37):5133-41, 2009.

41. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339:b3884, 2009.

42. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 97(9):1322-8, 2007.

43. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 27(2):127-47, 2009.

44. Hibbitts S . Should boys receive the human papillomavirus vaccine? Yes. BMJ 339:b4928, 2009.

45. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337:a769; 2008.

46. Cuschieri K. Should boys receive the human papillomavirus vaccine? No. BMJ 339:b4921, 2009.

47. Brisson M, Van de Velde N, Boily MC. Modeling the incremental impact of vaccinating boys against HPV. Oral presentation 440. 26th International Papillomavirus Conference, Montreal, Canada, (July 3-8, 2010).

48. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis, 2010.

49. Stone KM, Karem KL, Sternberg MR et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186(10):1396-402, 2002.

50. *Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199:926-35, 2009.
*Evidence of cross protection for HPV 31.

51. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 324:17-27, 2004.

52. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 199(7):919-22, 2009.

53. Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 102(5):325-39, 2010.

54. Edgren G, Sparen P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol 8(4):311-6, 2007.

55. *Munoz N, Manalastas R, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11,16, 18) recombinant vaccine: a randomised double-blind trial in adult women between 24 and 45 years of age. Lancet 373:1949-57, 2009.
*Primary data for efficacy of Gardasil for use in women 24-45 years.

56. FUTURE I/II Study Group et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341:c3493, 2010.

57. de Bie RP, van de Nieuwenhof HP, Bekkers RL, et al. Patients with usual vulvar intraepithelial neoplasia-related vulvar cancer have an increased risk of cervical abnormalities. Br J Cancer 101:27-31, 2009.

58. van de Nieuwenhof HP, Massuger LF, van der Avoort IA, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer 45:851-6, 2009.

59. Lilic V, Lilic G, Filipovic S, Visnjic M, Zivadinovic R. Primary carcinoma of the vagina. J BUON 15:241-7, 2010.

60. Baumann KH, Müller O, Naujok HB, Mann E, Barth P, Wagner U. Small-Area Analysis of Incidence and Localisation of Vulvar Cancer. Journal of Oncology. doi:10.1155/2010/512032.

61. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 85:499-502, 2009.

62. Hoy T, Singhal PK, Willey VJ, Insinga RP. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 25(10):2343-51, 2009.

63. Dorans K. Fewer shots proposed to increase uptake of HPV vaccine. Nat Med 16(8):832-3, 2010.

64. Dobson S, Dawar M, Kollmann T, et al. P-690: A two dose HPV vaccine schedule in girls: Immunogenicity at 24 months. Presented at 26th International Papillomavirus Conference, Montreal Canada, (July 3-8, 2010).

65. Pacher SK, Rosenthal HE, Perlitz H, et al. Direct Longitudinal comparison over 12 month of T cell responses to prophylactic HPV vaccines. Presented at 26th International Papillomavirus Conference, Montreal, Canada, (July 3-8, 2010).

66. Einstein MH, on behalf of the HPV-010 Study Group. Immunogenicity comparison of two prophylactic human papillomavirus cervical cancer vaccines at month 18. Presentation number PS 3-4. EuroGin, Monte Carlo, Monaco, (Feb 17-20, 2010).

67. *Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25:4931-4939, 2007.
*This work shows the loss of antibody titer women have for HPV 6/11/16/18 over time.

68. *Rowhani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 27:5612-5619, 2009.
*This work shows that nearly 15% of women lose antibodies for HPV 16 after 8.5 years of Gardasil vaccination.

69. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95:1459-66, 2006.

70. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10(1):108-15, 2003.

71. Safaeian M, Porras C, Schiffman M, et al. Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections. J Natl Cancer Inst. 2010 Oct 13. [Epub ahead of print]. 102(21), 1653-1662 (2010).

72. Block SL, Nolan T, Sattler C, et al: Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118:2135-2145, 2006.

73. *Harper DM. Primary Prevention of HPV-Associated Diseases. Public Health Genomics 12:319-330, 2009.
*This work highlights the fabulous antibody response to Gardasil in women already infected at the time of vaccination.

74. Villa LL, Ault KA, Giuliano AR, et al: Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24:5571-5583, 2006.

75. **Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler 15:116-9, 2009.
**Safety reports confirmed by independent specialists are notable in that the reports continue to be published as more vaccines are distributed.

76. Centers for Disease Control and Prevention. Syncope after vaccination - United States, January 2005-July 2007. Morb Mortal Wkly Rep 57:457-60, 2008.

77. Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C. Acute disseminated encephalomyelitis following vaccination against human papillomavirus. Neurology 72:2132-3, 2009.

78. Huang E, Strober J, Lomen-Hoerth C. Demyelination and Severe Loss of Spinal Motor Neurons following HPV vaccination. Abstract number WIP-19. American Neurological Association 134th Annual Meeting. (October 13, 2009). Report of motor neuron disease after HPV vaccine-http://www.medscape.com/viewarticle/711461 [accessed October 31, 2010].

79. McCarthy JE, Filiano J. Opsoclonusmyoclonus after human papillomavirus vaccine in a pediatric patient. Parkinsonism Relat Disord 15:792-4, 2009.

80. Cohen SM. Multiple evanescent white dot syndrome after vaccination for human papillomavirus and meningococcus. J Pediatr Ophthalmol Strabismus 25:1-3, 2009.

81. Menge T, Saleh A, Aktas O, Hartung HP, Methner A, Kieseler B. A case of fulminant neuromyelitis optica associated with quadrivalent HPV vaccination. Abstract MS Variants-2. Presented at 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis. (September 9-12, 2009).

82. *Souayah N, Michas-Martin PA, Nasar A, et al. Guillain-Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006-2009.Vaccine. (2010), doi:10.1016/j.vaccine.2010.09.020.
*Well researched documentation of increased incidence of a very rare side effect of Gardasil.

83. McGrogan A, Madle GC, Seaman HE, deVries CS. The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review. Neuroepidemiology 32(2):150-63, 2009.

84. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, Eddins DL, Bryan JA. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 110(2):105-23, 1979.

85. Preliminary Results: Surveillance for Guillain-Barré Syndrome After Receipt of Influenza A (H1N1) 2009 Monovalent Vaccine - United States, 2009-2010. Morbidity and Mortality Weekly Report (MMWR). 59:657-661, 2010.

86. Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 133:940-51, 1991.

87. Wheeler CM, Bautista OM, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26:686-96, 2008.

88. Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics 125:1142-51, 2010.

89. Vesikari T, Van Damme P, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 29:314-8, 2010.

90. Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 114:1170-8, 2009.

91. Coupe VMH, van Ginkel J, de Melker HE, Snijders PJF, Meijer CJLM, Berkhof J. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model-based cost-effectiveness. Int J Cancer 124:970-978, 2009.

92. de Kok IMCM, van Ballegooijen M, Habbema JDF. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 101:1083-92, 2009.

93. Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine 26 Suppl 11:L59-72, 2008.

94. Kim JJ, Goldie SJ. Health and economic implication of HPV vaccination in the United States. N Engl J Med 359:821-32, 2008.

95. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 26 Suppl 10: K76-86, 2008.

96. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of Human Papillomavirus Vaccination in the United States. Emerging Infectious Diseases 14:244-251, 2008.

97. Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis. Vaccine 27(43):6060-79, 2009.

98. Gericke CA . Paradox of vaccination in cervical cancer and screening. BMJ 337:a1049, 2008.

99. *Colgrove J, Abiola S, Mello MM. HPV vaccination mandates--lawmaking amid political and scientific controversy. N Engl J Med 363(8):785-91, 2010.
*An important study from the policy angle on HPV vaccination.

100. *Rothman SM, Rothman DJ. Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA 302(7):781-6, 2009.
*An important report highlighting the excessive marketing Merck pursued to sell Gardasil.

101. Committee on Adolescence. Achieving Quality Health Services for Adolescences. Pediatrics 121:1263-1270, 2008.

102. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26:201-9, 2007.

103. *Olsson SO, Paavonen J. Impact of HPV 6/11/16/18 vaccine on abnormal Pap tests and procedures. Oral presentation O-01.08 at 25th International Papillomavirus Conference, Malmo Sweden, (May 8-14, 2009).
*This work is important to note because the data contained herein show the true benefit of Gardasil in countries with cervical cancer screening.

104. http://www.who.int/hpvcentre/en/ [accessed October 31, 2010]

105. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 [accessed October 31, 2010]

106. http://www.cancer.org/cancer/vaginalcancer/detailedguide/vaginal-cancer-risk-factors [accessed October 31, 2010]

107.http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM190978.pdf [accessed October 31, 2010]

108.http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/../VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM184997.ppt [accessed October 31, 2010]

109.http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM190977.pdf [accessed October 31, 2010]

110. www.fda.gov/downloads/AdvisoryCommittees/.../UCM183842.ppt [accessed October 31, 2010].

111. http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct10/08-4-hpv-MaleTrails.pdf [accessed Nov 6, 2010]

112. http://vaers.hhs.gov/data/data/ [accessed October 31, 2010].

113. http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct10/08-2-hpv-VaccSafety.pdf [accessed Nov 6, 2010]

114. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111274.pdf [accessed October 31, 2010].

115. http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-feb10/02-2-hpv.pdf [accessed October 31, 2010]

116. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5932a3.htm?s_cid=mm5932a3_w [accessed October 31, 2010]

117. http://whqlibdoc.who.int/aide-memoire/a87773_eng.pdf [accessed October 31, 2010].

118. 71. http://www.hrsa.gov/vaccinecompensation/statistics_report.htm#claims_filed [accessed October 31, 2010].

119. http://www.medscape.com/viewarticle/559807 [accessed October 31, 2010]

120. http://www.reuters.com/article/idUSN2724270420101027 [accessed October 31, 2010]

121. http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con102926.pdf [accessed January 10, 2011]

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
-->